OBJECTIVE: To investigate the roles of angiogenesis, thrombospondin-1 (TSP-1) and transforming growth factor-β1 (TGF-β1) in invasive and noninvasive prolactinoma. METHODS: TSP-1 and TGF-β1 protein were examined using immunohistochemistry and Western blotting in 81 prolactinomas. Angiogenesis was assessed by measuring microvessel density via CD34 immunostaining. RESULTS: Microvessel density was significantly higher in invasive prolactinomas than in noninvasive prolactinomas. Immunohistochemistry demonstrated that significantly fewer invasive prolactinomas were positive for TSP-1 compared with noninvasive prolactinomas (17.9% versus 50.0%, respectively), and significantly higher numbers of invasive prolactinomas were positive for TGF-β1 compared with noninvasive prolactinomas (82.1% versus 42.9%, respectively). Microvessel density was significantly lower in TSP-1-positive prolactinomas than in TSP-1-negative prolactinomas, and significantly higher in TGF-β1-positive prolactinomas than in TGF-β1-negative prolactinomas. CONCLUSIONS: These results suggest a close relationship between angiogenesis and tumour invasiveness in prolactinoma. TSP-1 and TGF-β1 may play important roles in the progression of prolactinoma, by affecting angiogenesis.
SchlechteJA: Clinical practice. Prolactinoma. N Engl J Med2003; 349: 2035–2041.
2.
BarkerFG2ndKlibanskiASwearingenB: Trans-sphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab2003; 88: 4709–4719.
3.
AhmadiJNorthCMSegallHD: Cavernous sinus invasion by pituitary adenomas. AJR Am J Roentgenol1986; 146: 257–262.
4.
GürlekAKaravitakiNAnsorgeO: What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol2007; 156: 143–153.
5.
OffersenBVBorreMOvergaardJ: Quantification of angiogenesis as a prognostic marker in human carcinomas: A critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer2003; 39: 881–890.
SvagzdysSLesauskaiteVPavalkisD: Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer2009; 9: 95.
8.
PakalniskisMGWellsWASchwabMC: Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer?Radiology2011; 259: 365–374.
9.
TurnerHENagyZGatterKC: Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Metab2000; 85: 1159–1162.
10.
TurnerHENagyZGatterKC: Angiogenesis in pituitary adenomas—relationship to endocrine function, treatment and outcome. J Endocrinol2000; 165: 475–481.
11.
TakadaKYamadaSTeramotoA: Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr Pathol2004; 15: 131–139.
12.
MosherDFDoyleMJJaffeEA: Synthesis and secretion of thrombospondin by cultured human endothelial cells. J Cell Biol1982; 93: 343–348.
13.
JaffeEARuggieroJTLeungLK: Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc Natl Acad Sci USA1983; 80: 998–1002.
14.
JaffeEARuggieroJTFalconeDJ: Monocytes and macrophages synthesize and secrete thrombospondin. Blood1985; 65: 79–84.
15.
SilversteinRLNachmanRL: Thrombospondin binds to monocytes—macrophages and mediates platelet—monocyte adhesion. J Clin Invest1987; 79: 867–874.
16.
TarabolettiGRobertsDLiottaLA: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor. J Cell Biol1990; 111: 765–772.
17.
GuoNKrutzschHCInmanJK: Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res1997; 57: 1735–1742.
18.
LawlerJ: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med2002; 6: 1–12.
19.
VerrecchiaFMauvielA: Transforming growth factor-β signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol2002; 118: 211–215.
20.
DerynckRAkhurstRJBalmainA: TGF-β signaling in tumor suppression and cancer progression. Nat Genet2001; 29: 117–129.
21.
AdamsJCTuckerRP: The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn2000; 218: 280–299.
22.
KawatakiTNaganumaHSasakiA: Correlation of thrombospondin-1 and transforming growth factor-β expression with malignancy of glioma. Neuropathology2000; 20: 161–169.
23.
MiyanagaKKatoYNakamuraT: Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res2002; 22: 3941–3948.
24.
HardyJ: Transphenoidal microsurgical treatment of pituitary tumours. In: Recent Advances in the Diagnosis and Treatment of Pituitary Tumours (LinfootJ, ed). New York: Raven Press, 1979; pp 375–388.
25.
NakaoTKuritaNKomatsuM: Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol2011; 16: 145–152.
26.
WeidnerN: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol1995; 147: 9–19.
27.
CavallaroUChristoforiG: Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol2000; 50: 63–70.
28.
ChenZJLeHBZhangYK: Microvessel density and expression of thrombospondin-1 in non-small cell lung cancer and their correlation with clinicopathological features. J Int Med Res2009; 37: 551–556.
29.
WhiteJDHewettPWKosugeD: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res2002; 62: 1669–1675.
30.
KimJHSeoJSLeeBW: The characteristics of incidental pituitary microadenomas in 120 Korean forensic autopsy cases. J Korean Med Sci2007; 22 (suppl): S61–S65.
31.
JugenburgMKovacsKStefaneanuL: Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study. Endocr Pathol1995; 6: 115–124.
32.
VidalSKovacsKHorvathE: Microvessel density in pituitary adenomas and carcinomas. Virchows Arch2001; 438: 595–602.
33.
ViacavaPGasperiMAcerbiG: Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest2003; 26: 23–28.
34.
GoodDJPolveriniPJRastinejadF: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA1990; 87: 6624–6628.
35.
FontanaAFilleurSGuglielmiJ: Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int J Cancer2005; 116: 686–691.
36.
FebbraioMHajjarDPSilversteinRL: CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest2001; 108: 785–792.
37.
ReedMJIruela-ArispeLO'BrienER: Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. Am J Pathol1995; 147: 1068–1080.
38.
MiaoWMSengWLDuquetteM: Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-β-dependent and -independent mechanisms. Cancer Res2001; 61: 7830–7839.
StreitMVelascoPBrownLF: Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol1999; 155: 441–452.
41.
WangXQLindbergFPFrazierWA: Integrin-associated protein stimulates α2β1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol1999; 147: 389–400.
BreierGBlumSPeliJ: Transforming growth factor-β and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer2002; 97: 142–148.
44.
HasegawaYTakanashiSKanehiraY: Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer2001; 91: 964–971.
45.
XiongBGongLLZhangF: TGF β1 expression and angiogenesis in colorectal cancer tissue. World J Gastroenterol2002; 8: 496–498.
